A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

To learn if the drug combination of adagrasib, cetuximab, and cemiplimab can help to control metastatic CRC with KRAS G12C mutations.

Trial Details

NCT ID
NCT06412198
Phase
PHASE1 / PHASE2
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Cetuximab
  • Cemiplimab
  • Adagrasib
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Histologically confirmed diagnosis of advanced/metastatic microsatellite stable colorectal cancer with KRASG12C mutation with 1+ prior line(s) of t…
  • Confirmed KRASG12C mutation status. If a molecular profiling report is not available, a representative paraffin-embedded tumor block or a minimum o…
  • Unresectable or metastatic disease.
  • Participants must have received at least one prior line of chemotherapy for metastatic disease with progression on treatment or intolerance to ther…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →